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Summary Inhibition of protein kinase C (PKC) is discussed as a new approach for overcoming multidrug
resistance (MDR) in cancer chemotherapy. For evaluation of this concept we applied the bisindolylmaleimide
GF 109203X, which shows a highly selective inhibition of PKC isozymes a, /31, ,B2, y, 6 and e in vitro. The
efficacy of this compound in modulation of MDR was examined using several P-glycoprotein (P-gp)-
overexpressing cell lines including a MDRI-transfected HeLa clone, and was compared with the activities of
dexniguldipine-HCl (DNIG) and dexverapamil-HCl (DVER), both ofwhich essentially act via binding to P-gp.
As PKCa has been suggested to play a major role in P-gp-mediated MDR, cell lines exhibiting different
expression levels ofthis PKC isozyme were chosen. On crude PKC preparations or in a cellular assay using a c-
fos(-71I)CAT-transfected NIH 3T3 clone, the inhibitory qualities of the bisindolylmaleimide at submicromolar
concentrations were demonstrated. At up to 1 gm final concentrations of the PKC inhibitor GF 109203X, a
concentration at which many PKC isozymes should be blocked substantially, no cytotoxic or MDR-reversing
effects whatsoever were seen, as monitored by 72 h tetrazolium-based colorimetric MTT assays or a 90 min
rhodamine 123 accumulation assay. Moreover, depletion of PKCa by phorbol ester in HeLa-MDR1
transfectants had no influence on rhodamine 123 accumulation after 24 or 48 h. MDR reversal activity of GF
109203X was seen at higher final drug concentrations, however. Remarkably, [3H]vinblastine-sulphate binding
competition experiments using P-gp-containing crude membrane preparations demonstrated similar dose
dependencies as found for MDR reversion by the three modulators, i.e. decreasing efficacy in the series
dexniguldipine-HCl>dexverapamil-HCl>GF 109203X. Similar interaction with the P-gp in the micromolar
concentration range was revealed by competition of GF 109203X with photoincorporation of [3H]azidopine
into P-gp-containing crude membrane preparations. No significant effect of the PKC inhibitor on MDR1
expression was seen, which was examined by cDNA-PCR. Thus, the bisindolylmaleimide GF 109203X
probably influences MDR mostly via direct binding to P-gp. Our work identifies the bisindolylmaleimide GF
109203X as a new type of drug interacting with P-gp directly, but does not support the concept of a major
contribution of PKC to a P-gp-associated MDR, at least using the particular cellular model systems and the
selective, albeit general, PKC inhibitor GF 109203X.
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Specific sites of the human P-gp have been shown to be
phosphorylated Say PKC (Chambers et al., 1993), and an
interdependence of P-gp phosphorylation, PKC activity, P-gp
activity and multidrug resistance is indicated by the work of
several groups (Hamada et al., 1987; Yu et al., 1991;
Chambers et al., 1992; Bates et al., 1993). In particular,
PKCa appears to be involved in activation of the drug
transporter (Yu et al., 1991; Ahmad and Glazer, 1993).
Moreover, PKC has been discussed as part of a stress
response activating MDR] gene expression (Chaudhary and
Roninson, 1993; Grunicke et al., 1994). Thus, inhibition of
PKC has emerged as a new approach for overcoming MDR
in cancer chemotherapy. So far, rather non-specific kinase
inhibitors have been used to investigate the involvement of
PKC in MDR. The bisindolylmaleimide GF 109203X, which
is identical to Go 6850 (Figure 2a), shows highly selective
inhibition of many PKC isozymes in vitro. Thus, using
preparations of PKCa, -,B1, -/32, -y, -6 and -s from
recombinant cell clones, IC50 values between 20 nm and
200 nM were measured. Other kinases were affected at
distinctly higher concentrations (Toullec et al., 1991;
Martiny-Baron et al., 1993; Hartenstein et al., 1993), e.g.
PKC 4 (IC50 5.8 gM), PKA (cAMP-dependent protein kinase;
IC50 33 gM), G-kinase (cGMP-dependent kinase; IC50 4.6 gM)
or tyrosine kinases (IC50 94 /uM). The compound GF 109203X
retains its PKC inhibitory quality in cellular assays (Toullec
et al., 1991; Heikkila et al., 1993; Le Panse et al., 1994). This
PKC inhibitor is therefore suited to address the issue.
In principle, a chemosensitiser might affect P-gp-associated
MDR (1) by direct interaction with the P-gp; (2) by
modulation of P-gp activity indirectly, e.g. via inhibition of
phosphorylation by protein kinases; or (3) by altering
MDR1/P-gp gene expression. In order to discriminate
between these possible mechanisms we applied different
methodical approaches for testing the MDR modulating
activities of three different types of compounds on a series of
cell lines expressing P-gp and PKCa at various levels. Thus,
the effects of the bisindolylmaleimide PKC inhibitor GF
109203X were compared with the activities of the enantio-
meric pure dihydropyridine dexniguldipine-HCl (DNIG,
B8509-035) and the phenylalkylamine dexverapamil-HCl
(DVER; for structures see Figure 2b and c). The last two
compounds modulate a P-gp-associated MDR accordingly by
direct interaction with P-gp (Yusa and Tsuruo, 1989;
Hofmann et al., 1995; Borchers et al., 1995). DNIG also
exhibits PKC-inhibitory qualities (Uberall et al., 1991),
however only at about 100-fold higher concentrations
compared with the bisindolylmaleimide GF 109203X. Thus,
it appeared important to elucidate the relevance of PKC on
P-gp-associated MDR by comparing MDR reversal efficacies
of a specific PKC inhibitor and structurally different drugs
essentially interacting with P-gp directly. Our approach might
help to evaluate the concept of developing such drugs for
overcoming MDR in the clinics.
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Materials and methods
Cell lines
NIH 3T3 fibroblast cells (obtained from the ATCC), the
human adenocarcinoma cell line KB 3.1 and its MDR subline
KB 8.5 (Akiyama et al., 1985), the human T-cell leukaemia
cell line CCRF-CEM (ATCC CLL 119) and its MDR
sublines CCRF VCR 1000 and CCRF ADR 5000 were
maintained as described previously (Uberall et al., 1991;
Hofmann et al., 1995; Kimmig et al., 1990). Stable
transfection of HeLaS3 adenocarcinoma cells (ATCC CCL
2.2) using the purified pSKI.MDR expression vector
construct (Kane et al., 1989) and maintenance of the MDR
cell clone HeLa-MDRI was reported recently (Hofmann et
al., 1995). The multidrug-resistant sublines were routinely
cultured drug free 1 -2 weeks before starting experiments. All
cell lines used for experimentation were tested to be free of
mycoplasma.
Drugs
Dexniguldipine-HCl (B8509-035, DNIG) was provided by Dr
W-R Ulrich (Byk Gulden GmbH, Konstanz, Germany); GF
109203X (identical with Go 6850) and dexverapamil-HCl
[R(+)-verapamil, DVER] were purchased from Calbiochem
(Bad Soden, Germany) or RBI (Natick, USA) respectively.
Staurosporine (STAU), phorbol 12-myristate 13-acetate
(PMA =TPA) and phorbol-12,13-dibutyrate (PDBu) were
purchased from Sigma (Deisenhofen, Germany). These
compounds were all dissolved using glassware as 10 mM
stock solutions in dimethyl sulphoxide (DMSO). Rhodamine
123, vincristine sulphate (VCR), colchicine and doxorubicin-
HCl (doxorubicin, DOX) were also purchased from Sigma,
vinblastine sulphate (VELBE®) from Ely Lilly (Giessen,
Germany).
PKC activity assay
Total PKC was partially purified from NIH 3T3 cells and its
activity was assayed as described recently (Uberall et al.,
1994) by detecting the incorporation of 32p from [_y-32P]ATP
(specific activity 30 Ci mmol-'; NEN, Vienna, Austria) for
15 min at 32°C into histone H1 (calf thymus type III) in the
presence of 1 giM phosphatidyl-L-serine, 1.8 gM 1,2-diocta-
noyl-rac-glycerol and a final concentration of 50 gIM non-
labelled ATP.
CAT assay for measuring fos-promoter activity
The effect of compounds on the activity of the human c-fos
promoter were tested after stable transfection of NIH 3T3
cells by a c-fos(-711)CAT reporter plasmid construct (Konig
et al., 1989) obtained from Dr P Herrlich, Karlsruhe,
Germany, containing the human c-fos promoter linked to
the chloram,phenicol acetyltransferase (CAT) reporter gene as
described (Uberall et al., 1991; 1994).
Western immunoblotting
The preparations of the various protein fractions and the
transfer onto Immobilon-P membranes (Millipore, Eschborn,
Germany) were performed as described (Kimmig et al., 1990;
Neumann et al., 1992; Hofmann et al., 1995). After blocking
with 5% non-fat dried milk in PBS for 6 h at 20°C, the
membranes were incubated for 16 h at 4°C with 1 Mg ml-' of
the PKCa-specific polyclonal antibody PK1O (Oxford
Biomedical Research, Oxford, USA). After three washing
steps at 20°C (15 min each) in TBS/T buffer [4 mM Tris-HCl
(pH 7.5), 100 mM sodium chloride, 0.05% Tween 20], the
membranes were incubated for 2 h at 20°C with a horse-
radish-peroxidase-conjugated anti-rabbit IgG antibody (Dia-
nova, Hamburg, Germany) in TBS/T at a dilution of
1:100 000. After washing three more times in TBS/T the
membranes were incubated with a solution containing 50%
luminol and 50% enhancer (ECL detection system, Amer-
sham, Braunschweig, Germany) as described by the
manufacturer. The membranes were then exposed using
Hyperfilm-ECL (Amersham). The films were processed as
recommended by the supplier.
PCR gene expression analysis
Preparation of total cellular RNA, synthesis of cDNA using
random hexanucleotide primers (Boehringer Mannheim,
Germany) and RAV2 reverse transcriptase (Amersham), the
PCR using MDRl-specific amplimers (expected size of the
amplified material, 229 bp), and the quantitative analysis of
the amplified material were performed as reported earlier
(Beck et al., 1995a). The amplimers for MDR1 and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) were adopted
from earlier studies (Gekeler et al., 1990; Beck et al.,
1995a). For GAPDH amplification 23 cycles were applied
throughout (expected size of the amplified material, 358 bp).
The latter was included as a control for the amount ofcDNA
present in the samples. The signal intensities were evaluated
by the CS-1 videoimager system (Cybertech, Berlin,
Germany) and normalised to the signal intensities obtained
using the GAPDH specific amplimers.
Drug sensitivity testing
For determination of drug sensitivities of the cell lines in the
absence or presence of modulators the tetrazolium-based
colorimetric MTT assay (Mosmann, 1983) was performed as
described recently (Gekeler et al., 1995). Cell aliquots were
seeded in triplicate into 96-well microtitre plates and
incubated for 72 h. The dose-response curves of resistance
modulation were calculated from series of MTT assays in
which the turning points of the curves found (mean of at
least two independent experiments), applying the anti-cancer
drug in the absence or presence of fixed final concentrations
of the modulators, were shifted towards the dose-response
curve produced by the same anti-cancer drug on the parental
cells without a modulator. A complete shift into the curve of
the parental cell line was set to 100% reversal. A further
shift, however, could mean that the drug sensitivity of the
parental cell line is also enhanced, which might be explained
by the presence of inherent drug resistance mechanisms more
or less affected by the chemosensitisers, or by other as yet
mechanistically unknown synergistic effects of the drugs given
in combination.
Rhodamine 123 accumulation
The assay was performed essentially as described recently
(Boer et al., 1994). Briefly, the cells were sedimented and
resuspended in culture medium without serum. A pH value of
7.3 was adjusted by 10 mM HEPES and incubated in a total
volume of 1 ml in the presence of modulators or solvent (1%
DMSO) for 30 min at 37°C. Glass tubes were used for all
experiments. Rhodamine 123 was added to a final concentra-
tion of 800 ng ml-'. Incubation was continued for 60 min.
Cells were analysed on an Epics Profile II FACS (Coulter,
Krefeld, Germany). The excitation wavelength was 488 nm
and the cell-associated rhodamine 123 fluorescence was
measured at 520 nm.
Radioligand binding experiments and photoaffinity labelling
Crude membranes were prepared from CCRF-CEM and
CCRF ADR 5000 cells as described above. Aliquots of 15 ,ug
ofprotein were incubated with 40 nM [3H]vinblastine sulphate
(specific activity 2.6 Ci mmol-') without or with the various
compounds in a final volume of 250 ,ul in 50 mM Tris-HCl/
0.1 mM phenylmethylsulphonyl fluoride (PMSF) (pH 7.4).
Non-specific binding was determined in the presence of
10 jgM unlabelled vinblastine sulphate. After 1 h at 37°C the
bound radioligand was separated by rapid vacuum filtrationover glassfibre filters. The filter-bound radioactivity was
quantified by liquid scintillation counting. Photoaffinity
labelling using [3H]azidopine (Amersham) and inhibition
thereof by GF 109203X was also performed using crude
membrane preparations from CCRF ADR 5000 cells or
CCRF-CEM cells as a control (Borchers et al., 1995). After
separation of the photolabelled proteins by SDS-polyacryla-
mide gel electrophoresis, fluorography was used for measure-
ment of photoincorporation into the 170 kDa band
representing P-glycoprotein as described recently (Borchers
et al., 1995). The labelling of material prepared from the
parental cell line CCRF-CEM was negligible.
Results
Gene expression and drug sensitivities of cell lines
The expression levels of the MDR1/P-gp and the PKCa
genes, and the sensitivities of cell lines to vincristine,
doxorubicin or the chemosensitisers are listed in Table I. P-
gp expression levels were adopted from previous studies
(Kimmig et al., 1990; Hofmann et al., 1995) where the
monoclonal antibodies C219 or C494 have been used for
Western immunoblottings respectively. Accordingly, the cell
lines show very different levels ofP-gp roughly corresponding
to the extent of drug resistance. The expression analysis of
PKCa by Western immunoblotting using total cellular
protein preparations and the polyclonal antibody PK1O
demonstrates substantial differences in the expression of this
particular PKC isozyme (Figure 1). While low or even absent
PKCa expression was found in the parental T-lymphoblas-
toid cell line CCRF-CEM and its MDR subline CCRF VCR
1000, the MDR subline CCRF ADR 5000 showed a
significantly increased PKCac expression. On the other hand,
the KB cell lines showed distinct, but the HeLa cell lines even
stronger, PKCa expression. These results obtained by
Western immunoblottings correspond well with data ob-
tained by a cDNA-PCR gene expression analysis performed
with RNA from the same cell lines according to Beck et al.
(1995b). However, in the KB cell lines PKCa was mainly
found in the membrane fraction (data not shown), while in
HeLa cells a major part of this enzyme appeared in the
cytosolic protein fraction (see Figure 10).
While staurosporine, as expected, inhibited cell growth in
the nanomolar concentration range, the bisindolylmaleimide
GF 109203X did not produce any anti-proliferative activity
up to 2 jgM, or even 10 gM, depending on the cell line. DNIG
showed anti-proliferative/cytotoxic activity at similar concen-
trations to GF 109203X, while dexverapamil-HCl usually did
not stop cellular growth completely up to a final concentra-
tion of 100 gM. Interestingly, we observed an association of
P-gp expression with the sensitivity of the cell lines towards
these agents. Thus, a collateral sensitivity of CCRF ADR
5000 cells to DNIG and dexverapamil-HCl was seen (a
detailed analysis of this phenomenon will be published
elsewhere). In contrast, an up to 8-fold resistance of MDR
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sublines towards staurosporine or GF 109203X was detected
(Table I), suggesting an involvement of P-gp in export of
these latter compounds from the cells.
PKC inhibition by GF 109203X, DNIG and DVER
PKC inhibition was examined using crude preparations of
total PKC from NIH 3T3 cells. The efficient PKC inhibition
by GF 109203X in the nanomolar concentration range (IC50,
22.5 nM) is shown in Figure 2a. DNIG produced only a
partial inhibition at concentrations higher than 10 ,uM (Figure
2b), but dexverapamil-HCl was virtually inactive (Figure 2c).
To demonstrate further that the bisindolylmaleimide retains
its PKC-inhibitory quality in a cellular assay also, NIH 3T3
cells were stably transfected with a c-fos(-711)CAT reporter
plasmid construct, and the phorbol ester-stimulated c-fos
promoter activity, which accordingly depends on PKC
(Uberall et al., 1994), was examined after incubation with
or without the bisindolylmaleimide GF 109203X or DNIG
respectively. While the PKC inhibitor GF 109203X did not
significantly influence the basal activity of the c-fos promoter,
the phorbol ester-stimulated c-fos promoter activity was
inhibited in a dose-dependent manner already showing a
distinct effect at 50 nM (Figure 3), similar to the inhibitory
action of DNIG applied at a 100-fold higher final
concentration. Thus, together with the results published by
other authors (Toullec et al., 1991; Heikkila et al., 1993; Le
Panse et al., 1994), we have no reason to suspect an abolition
of the specific PKC-inhibitory qualities of GF 109203X in
cellular assays. Moreover, the 72 h MTT assay performed
with the NIH 3T3 cells revealed an IC50 value of 8.5 gM for
GF 109203X, which does not indicate some peculiarities of
these cells compared with the other cell types used in the
present work.
MDR reversal by GF 109203X, DNIG and DVER
Various methods were applied to demonstrate a MDR
reversing activity of the three compounds in different MDR
sublines. Figure 4 demonstrates the dose-dependent modula-
tion of the vincristine resistance of CCRF VCR 1000 cells by
DNIG applying the 72 h MTT assay. Figure Sa compares the
effects of DNIG and the bisindolylmaleimide on vincristine
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Figure 1 Western immunoblotting using total cellular protein
fractions of the cell lines CCRF-CEM (1), CCRF VCR 1000 (2),
CCRF ADR 5000 (3), KB 3.1 (4), KB 8.5 (5), HeLa-WT (6) and
HeLa-MDR1 (7), and the PKCac-specific polyclonal antibody
PK1O. Loading was 50pg per lane; size marker (8).
Table I Gene expression and drug sensitivities of the cell lines
P gpa PKCd VCRb DOXb GF 109203XC STAEc DNIGC DVERC
NIH3T3 NA NA 1 1 8.5 NA 6.5 30
CCRF-CEM (+) (+) 1 1 5 0.014 4.5 80
CCRF VCR 1000 + + 8300 220 8 NA 5 100
CCRF ADR 5000 + + + + 19800 6400 30 0.120 1.1 55
KB 3.1 (+) + + 1 1 NA NA 5 100
KB 8.5 + + + 100 10 7 NA 5 100
HeLa-WT - + + + 1 1 18 NA 5 200
HeLa-MDRI + + +++ 56 360 23 NA 6 200
ap-gp expression levels estimated byWestern immunoblotting were adopted from previous studies (Kimmig et al., 1990; Hofmann et al., 1995);
PKCa expression levels were estimated by Western immunoblotting according to Figure 1; -, also by cDNA-PCR no signal was found, +, a very
low expression at the protein level, but also by cDNA-PCR a signal was seen (Gekeler et al., 1994; and unpublished results). bRelative resistances
were calculated from the ratio ofthe IC50 value obtained by 72h MTT assays seen with the MDRcell line and the IC50 value seen with theparental
cell line respectively. CICSO (gM) values obtained by 72h MTT assays are fisted. NA, not assayed.Effects of GF 109203X on P-gp-mediated MDR
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or doxorubicin resistances of CCRF VCR 1000 cells
monitored by such MTT assays. The resistance reversion
curves are compared with the results obtained with the same
compounds and cells using the rhodamine 123 accumulation
assay (Figure 5b). In both assays the PKC inhibitor showed
similar activity starting at a final drug concentration above
2 gM. This seems remarkable in view of the largely different
assay conditions applied, i.e. incubation time 72 h vs 90 min
and the presence or absence of 10% fetal calf serum (FCS).
DNIG, however, modulated P-gp functions in either assay
efficiently at final drug concentrations below 1 guM showing
somewhat higher efficacies in the absence of FCS.
To address the question of a direct interaction of the
bisindolylmaleimide GF 109203X with P-gp we used the cell
line CCRF ADR 5000, which overexpresses the P-gp at a
very high level. The results obtained with this cell line by
MTT assays were compared with drug competition experi-
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ments using crude membrane preparations and
[3H]vinblastine sulphate as a radioligand. Figure 6a demon-
strates that the bisindolylmaleimide shows slight MDR
reversal at 10 ,uM, whereas 2 /IM DNIG reversed the
vinblastine resistance of this MDR subline by about 50%.
The rank order of activity, i.e. DNIG>DVER>GF
109203X, is mirrored by the radioligand competition
experiments (Figure 6b), suggesting a direct interaction of
the compounds with P-gp at concentrations also active in the
biological MDR reversal assay. Competition of
[3H]vinblastine sulphate binding by unlabelled vinblastine
sulphate was included as a control.
Because the MDR sublines of the human T-lymphoblas-
toid cell line CCRF-CEM show rather low expression of
PKCa, we additionally investigated the MDR reversal
capacity of the compound GF 109203X on cell lines
exhibiting distinct expression of this PKC isozyme. There-
fore, the MDRI/P-gp transfectant HeLa subclone HeLa-
MDR1 and the cell line KB 8.5 were included in the study.
Figure 7a shows the dose-dependent reversion of vincristine
or doxorubicin resistances of HeLa-MDRI cells by GF
109203X or DNIG respectively. In good correspondence to
the data shown above, the PKC inhibitor produced effects
only at concentrations higher than 1 ^uM, in contrast to
DNIG. Remarkably, however, using GF 109203X a complete
reversal of both resistances was achieved, while DNIG could
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Figure 3 Cellular assay measuring the effects (mean+standard
deviation, n=3) of GF 109203X at 50nM, 1gM, 10 iM or of
DNIG at 5,UM final concentrations on phorbol ester-induced c-fos
promoter activity using a c-fos(-711) CAT plasmid construct
transfected into NIH 3T3 fibroblasts.
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Figure 2 In vitro inhibition (mean+standard deviation, n = 3) of
PKC by (a) GF 109203X, (b) DNIG or (c) DVER measured on
crude PKC preparations from NIH3T3 fibroblasts.
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Figure 4 Dose-dependent modulation of the vincristine resis-
tance of CCRF VCR 1000 cells by DNIG determined by 72h
MTT assays.
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CHreverse the doxorubicin resistance of this MDR1 transfectant
clone by only about 70%. As we observed a > 100%
reversion of the vincristine resistance of HeLa-MDR1 cells
by both compounds, we examined the influence of DNIG or
the bisindolylmaleimide on the vincristine sensitivity of
parental HeLa cells. Figure 7b demonstrates such modulat-
ing effects of the compound GF109203X. A similar result was
obtained applying DNIG under the same conditions (data
not shown). As the parental HeLa cell line used for this study
shows virtually no MDR1 gene expression as examined by
cDNA-PCR (data not shown), some other as yet unknown
factor seems to be responsible for our observation.
The dose-dependent reversal of the drug resistances of KB
8.5 cells (Figure 8) by GF 109203X was almost identical to
the curves found for the HeLa transfectant. DNIG, again,
showed clearly higher efficacies, which were particularly
pronounced in the case of doxorubicin resistance modulation
on KB 8.5 cells. Interestingly, using this cell line, maximal
reversion of doxorubicin resistance approached 100%
applying either chemosensitiser.
Inhibition by GF 109203X of P-glycoprotein [3H]azidopine
photoaffinity labelling
To substantiate further a direct interaction of the bisindo-
lylmaleimide GF 109203X with P-gp, photoaffinity labelling
experiments were performed in the absence or presence of
various amounts of GF 109203X using crude membranes of
the cell line CCRF ADR 5000 and [3H]azidopine as already
described (Borchers et al., 1995). Inhibition of the photo-
affinity labelling was observed in a similar micromolar
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concentration range (Figure 9) as described above for
competition with [3H]vinblastine sulphate binding by GF
109203X.
MDR reversal after depletion ofPKCo* by phorbol ester
To elucidate further a contribution of PKCa to the MDR of
HeLa-MDR1 cells, 1 /iM TPA was used to deplete PKCa
which was proven by Western immunoblottings. After
phorbol ester treatment for 24 h or 48 h PKCa could no
longer be detected either in the cytosolic or in the membrane
fraction of the cells (Figure 10). Under these conditions the
rhodamine 123 transport was measured in the presence or
absence of the PKC inhibitor GF 109203X or DNIG
respectively. No influence of the PKC depletion whatsoever
could be observed however (Figure 11), whereas DNIG at a
1 ,UM final concentration produced a strong increase of the
cellular dye content as expected.
MDR] gene expression after treatment with GF 109203X
As PKC might influence the expression of the MDR1 gene,
we analysed the effect of the bisindolylmaleimide thereon by
cDNA-PCR. Thus, exponentially growing cultures of the cell
lines CCRF VCR 1000 and KB 8.5 were incubated with or
without GF 109203X for 24 h. To detect changes of relative
MDR1 mRNA levels the cDNA-PCR was performed
applying varying numbers of PCR cycles. The final
concentrations of the PKC inhibitor were between 5 jgM
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Figure 5 (a) Dose-dependent modulation of vincristine or
doxorubicin resistances of CCRF VCR 1000 cells by GF
109203X or DNIG respectively. The data originate from 72h
MTT assays as shown in Figure 4. (b) Modulation of rhodamine
123 accumulation (mean of two separate experiments) of CCRF
VCR 1000 cells by GF 109203X, DVER or DNIG.
0.01 0.1 1 10 100
Chemosensitiser (gM)
Figure 6 (a) Dose-dependent modulation of vincristine or
doxorubicin resistances of CCRF ADR 5000 cells by GF
109203X, DVER or DNIG. The data originate from 72h MTT
assays as shown in Figure 4. (b) [3H]Vinblastine sulphate binding
competition (all data points represent the mean of two separate
experiments) by GF 109203X, DVER, DNIG or vinblastine
sulphate, respectively, using crude membranes from CCRF ADR
5000 cells.
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and 10 gtM, similar to those causing MDR modulation in the
other assays, and where the series of PKC isozymes listed
above should be blocked. The data shown for KB 8.5 cells
(Figure 12a) or CCRF VCR 1000 cells (Figure 12b), clearly
demonstrate that under the chosen conditions the specific
PKC inhibitor GF 109203X does not influence MDR1 gene
expression.
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Discussion
Inhibition of PKC appears to be an intriguing new approach
for overcoming MDR eventually affecting two completely
different mechanisms simultaneously: (1) the inactivation of
P-gp via alteration of its phosphorylation status; and (2) the
suppression of MDR1 gene expression. The latter seems to be
especially attractive in view of reports on an anti-cancer
drug-mediated MDRl gene induction (Gekeler et al., 1988;
1994; Kohno et al., 1989; Chaudhary and Roninson, 1993)
which might represent a PKC-triggered stress response and
could therefore be attenuated by PKC inhibitors possibly
given together with anti-cancer drugs (Chaudhary and
Roninson, 1993; Grunicke et al., 1994). So far, rather non-
specific PKC inhibitors like staurosporine or the isoquinoline
sulphonamide derivative H7 were used to investigate the issue
(Chaudhary and Roninson, 1993). Therefore, we applied the
highly specific PKC inhibitor GF 109203X. Because of the
assumed involvement of PKCa in P-gp activity (Yu et al.,
1991; Ahmad and Glazer, 1993), cell lines exhibiting different
levels of PKCa expression were examined. To substantiate
the data further, some experiments using the phorbol ester
TPA for depletion of PKCc were performed. Other PKC
isozymes might be relevant for P-gp phosphorylation,
however. It has been described that phorbol ester treatment
also down-modulates PKC5 and PKCe, but leaves PKCC
unaffected (Szallasi et al., 1994). At least the genes for the
PKCe and PKCC isozymes are expressed at various levels in
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Figure 7 (a) Dose-dependent modulation of vincristine or
doxorubicin resistances of HeLa-MDRl cells by GF 109203X
or DNIG. The data originate from 72h MTT assays as shown in
Figure 4. (b) Effects of GF 109203X on the vincristine sensitivity
of HeLa-WT cells.
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Figure 9 Inhibition of [3H]azidopine photoaffinity labelling by
GF 109203X (mean of two separate experiments) using crude
membrane preparations of CCRF ADR 5000 cells. After UV
irradiation and separation of the labelled proteins on 8% SDS-
polyacrylamide gels the photoincorporation into the 170kDa
band was evaluated by fluorography and densitometry applying
the CS-1 videoimager system (Borchers et al., 1995).
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Figure 8 Dose-dependent modulation of vincristine or doxor-
ubicin resistances of KB 8.5 cells by GF 109203X or DNIG. The
data originate from 72h MTT assays as shown in Figure 4.
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Figure 10 Depletion of PKCa in cytosol or membrane protein
fractions after phorbol ester treatment of HeLa-WT or HeLa-
MDR1 cells respectively. Western immunoblottings were per-
formed using the PKCa-specific polyclonal antibody, PKIO. As
controls, protein preparations from rat brain were used, in which
the PKCa-specific signal could be distinctly diminished by adding
the block peptide provided by the supplier of the antibody.
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the cell lines used here, which was shown by a cDNA-PCR
approach (to be published elsewhere) according to Beck et al.
(1995b). Remarkably, in contrast to the CCRF-CEM cell line
and its sublines no expression of PKC,B1, PKC,B2 or PKCt
was detected in the KB cells and the HeLa cells. Although a
CY) O
C., C
CS)
O C SC
E
u JU bu
Time (min)
Figure 11 Rhodamine 123 accumulation (mean+standard
deviation, n =3) after treatment of HeLa-MDRI cells with 1gM
TPA for 24h in the absence or presence of 1 tM GF 109203X or
1 /M DNIG respectively. After a 48h TPA treatment virtually the
same result was observed (data not shown).
a
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Figure 12 Effects of GF 109203X on MDR1 gene expression
(mean+standard deviation, n=3) after a 24h incubation of (a)
KB 8.5 cells, and (b) CCRF VCR 1000 cells at the final
concentrations indicated. The cDNA-PCR was performed by
increasing the number of PCR cycles. The signal intensities were
calculated after normalisation onto the signal intensities obtained
by the GAPDH amplimers where 23 PCR cycles were applied
throughout, which was proven to be in the exponential range of
PCR yield.
somewhat higher MDR reversal activity by GF 109203X was
observed using the KB 8.5 or the HeLa-MDRI transfectant
cell line compared with the results obtained with the CCRF-
CEM-derived MDR sublines, we could not find a clear link
between MDR reversal efficacy of GF 109203X and PKC
isozyme expression levels in the various cell lines used.
Nonetheless, using the HeLa-MDR1 transfectant, down-
modulation of PKC by TPA showed virtually no effect
after 24 h or 48 h. Similar findings were published recently
using the P-gp overexpressing hamster MDR cell line CHRC5
and PDBu for down-modulation of PKC (Epand and
Stafford, 1993), or the P-gp and PKCa overexpressing
human breast carcinoma cell line MCF-7TH and TPA or
bryostatin 1 for down-modulation of PKC isozymes a and
(partly) £ (Scala et al., 1995).
We and others (Toullec et al., 1991; Heikkila et al., 1993;
Le Panse et al., 1994) have shown that the compound GF
109203X retains its PKC-inhibitory quality in assays using
vital cells, as distinct inhibition was seen there at final
concentrations below 1 gM. Some variation, however, of
PKC-inhibitory qualities of the compound GF 109203X in
various cellular assays could be explained by different
expression levels of Ca2+-dependent or Ca2'-independent
PKC isozymes (Martiny-Baron et al., 1993; Le Panse et al.,
1994).
As we excluded any modulation of MDR1 gene
expression by the bisindolylmaleimide after a 24 h incuba-
tion of two different types of MDR cells, i.e. a T-
lymphoblastoid CCRF-CEM subline and an adenocarcino-
ma KB subline (Figure 12), there is no reason to assume an
involvement of the PKC isozymes oa, #f1, #2, y, ( and s in
MDR1 gene expression under the conditions applied.
Considering the IC50 value of 5.8 /gM observed in vitro on
PKCC preparations (Martiny-Baron et al., 1993), even an
involvement of PKCC seems not very likely, because at least
some partial MDR1 mRNA down-modulation should be
expected at the concentrations applied (7.5 or 10 gLM GF
109203X), if such a link actually exists in the cell types
investigated here. It has to be emphasised, however, that our
results do not exclude a PKC-mediated impact on MDR1
gene expression becoming relevant as part of a rather
complex stress response (Chaudhary and Roninson, 1993) in
a transient manner possibly including other factors, by
analogy with our observation that only a stimulated c-fos
promoter activity is suppressed by the PKC inhibitor (Figure
3).
The dose-response curves of MDR modulation (Figures
4-8), showing half-maximal effects in the range of 3 gIM or
even higher final concentrations of GF 109203X, correspond
well to the dose-responses seen in radioligand
([3H]vinblastine sulphate) binding (Figure 6b) or photoaffi-
nity labelling ([3H]azidopine) competition experiments using
crude membrane preparations from CCRF ADR 5000 cells.
We therefore suggest that the observed MDR modulation by
the bisindolylmaleimide PKC inhibitor GF 109203X is
essentially caused by direct interaction of the compound
with P-gp. Then, the view appears justified that at least the
PKC isozymes accordingly inhibited by GF 109203X
strongly, i.e. a, P1I, ,B2, y, ( and £, do not contribute much
to the P-gp-mediated MDR in the cell systems used by us.
This also corresponds to the finding published recently
(Gupta et al., 1994) that calphostin C devoid of PKC-
inhibitory activity because of exclusion of light exposure,
modulates MDR in about the same manner as the activated
calphostin C. Even staurosporine accordingly binds to P-gp
(Sato et al., 1990; Miyamoto et al., 1993). Similar
observations were reported for the staurosporine derivative
NA-382 (Miyamoto et al., 1993). The recently reported
strong MDR-modulating effects (Utz et al., 1994) of another
staurosporine derivative (CGP 41251) could also be explained
by direct interaction with P-gp.
Our data indicate the need for investigating the direct
binding of MDR-modulating compounds to P-gp for
evaluation of the virtual mechanisms of action. It might
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not be surprising that many structurally rather complex
compounds usually derived from naturally occurring drugs
interact with P-gp.
Nonetheless, we did not investigate the phosphorylation of
cellular targets under the influence of GF 109203X as
described by Toullec et al. (1991). Thus, at present we
cannot state whether phosphorylation ofP-gp actually occurs
in the cell lines investigated here and at which final
concentrations the compound GF 109203X might influence
in a cellular assay the phosphorylation of P-gp and/or other
cellular PKC substrates. Moreover, a contribution to P-gp
activity of particular PKC isozymes like PKC; (as proposed
recently by Bates et al., 1993), poorly affected by GF
109203X, cannot be excluded. However, no influence of P-gp
phosphorylation on P-gp transport fumction was observed by
Scala et al. (1995). Moreover, an altered P-gp in which the
serines at positions 661, 667, 671, 675 and 683 were replaced
by non-phosphorylatable alanine residues showed neither
significant [39Porthophosphate incorporation nor a signifi-
cantly disturbed transport function (Germann et al., 1996).
Altogether, there is no experimental evidence for a major
contribution ofP-gp phosphorylation to MDR in a variety of
cell types and transfectants.
As it was shown previously (Toullec et al., 1991) that the
bisindolylmaleimide GF 109203X competes with ATP at
PKC, we speculate on an interaction of the drug with the
ATP binding site(s) of P-gp as well, which might also be true
for the reversal by GF 109203X ofthe MDR mediated by the
newly identified ABC (ATP binding cassette) drug transpor-
ter MRP (multidrug resistance associated protein) (Gekeler et
al., 1995). From our data it seems obvious, however, that
chemosensitisers binding to P-gp with high affinity (such as
DNIG) may be particularly valuable for clinical use as MDR
modulators. Nonetheless, the bisindolylmaleide represents
a new tool structure possibly binding to a site on P-gp
different from the binding site of DNIG, which supposedly
acts as an allosteric inhibitor ofP-gp according to Ferry et al.
(1992) and Malkhandi et al. (1994).
Abb
ATCC, American Type Culture Collection; CAT, chloramphenicol
acetyl transferase; cDNA-PCR, complementary DNA polymerase
chain reaction; DMSO, dimethylsulphoxide; DNIG, dexniguldi-
pine-HCLI DVER, dexverapamil-HCl; DOX, doxorubicin;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HEPES, 4-
(2-hydroxyethyl)-l-piperazine-ethanesulphonic acid; IC5o, 50%
inhibitory concentration; MDR, multidrug resistance; MDRl,
human MDR1 gene; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide; PBS, phosphate-buffered saline; PDBu,
phorbol-12,13-dibutyrate; P-gp, P-glycoprotein; PKC, protein
kinase C (EC 2.7.1.37); PMSF, phenylmethylsulphonyl fluoride;
STAU, staurosporine; TPA (=PMA), phorbol-12-myristate-13-
acetate; VCR, vincristine.
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